Andrea Gramegna

Dec 16, 2023 | respiratory-research.biomedcentral.com | Andrea Gramegna |Andrea Lombardi |Margherita Ori |Francesco Amati |Mariangela Retucci |Gianfranco Alicandro | +9 more

Treatment with low-dose azithromycin is beneficial in pwCF and chronic P. aeruginosa mainly due to its immunomodulatory and anti-inflammatory properties [106]. The efficacy of macrolides does not appear to derive from the antibiotic effect but is mediated by inhibiting biofilm formation and other bacterial virulence factors. This results in improved lung function and reduced exacerbation rates in this group of patients [107]. Macrolides are also a key drug in the clinical management of NTM-PD.

Nov 3, 2023 | resmedjournal.com | Andrea Gramegna |Stefano Aliberti |Pieve Emanuele |Maria Calderazzo

The advent of elexacaftor/tezacaftor/ivacaftor (ETI) resulted in unprecedented clinical benefits for eligible adults with CF. As a result, the question of whether chronic treatments can be safely stopped or adapted to this new situation has become a matter of great interest. Our objective was to derive a consensus among Italian experts on the impact of ETI on the current clinical management of CF lung disease.

Jun 6, 2023 | dialnet.unirioja.es | Stefano Aliberti |Andrea Gramegna |Manuela Seia |Francesco Malvestiti

Alpha1-Antitrypsin Inherited Variants in Patients With BronchiectasisStefano Aliberti[1];Andrea Gramegna[2];Manuela Seia[3];Francesco Malvestiti[4];Marco Mantero[2];Giovanni Sotgiu[5];Edoardo Simonetta[1];Daniele Prati[4];Stefania Paganini[3];Ilaria Ferrarotti[6];Elena Benzoni[3];Anna Stainer[1];Martina Santambrogio[2];Laura Saderi[5];Alice M. Balderacchi[6];Luca Valenti[7];Angelo G.